Comment submitted by B. Sachau
Posted : 11/06/2006     ID ：EPA-HQ-OAR-2006-0159-0025     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Placeholder for CONFIDENTIAL letter received by EPA from Robert M. Sussman of Latham and Watkins, LLC, counsel for Amphastar Pharmaceuticals Inc., and Armstrong Pharmaceuticals, Inc. on October 13, 2006.
Posted : 11/09/2006     ID ：EPA-HQ-OAR-2006-0159-0026     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Placeholder for CONFIDENTIAL attachment received by EPA from Robert M. Sussman of Latham and Watkins, LLC, counsel for Amphastar Pharmaceuticals Inc., and Armstrong Pharmaceuticals, Inc. on October 23, 2006.
Posted : 11/09/2006     ID ：EPA-HQ-OAR-2006-0159-0027     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Letter to Drusilla J. Hufford, Director, Global Programs Division, USEPA
Posted : 11/14/2006     ID ：EPA-HQ-OAR-2006-0159-0028     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Anonymous Public Comment
Posted : 11/24/2006     ID ：EPA-HQ-OAR-2006-0159-0029     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Comment submitted by Steven H. Bernhardt, Global Director, Regulatory Affairs, Honeywell Specialty Materials
Posted : 12/06/2006     ID ：EPA-HQ-OAR-2006-0159-0030     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Comment submitted by Peter A. Blenkinsop, International Pharmaceutical Aerosol Consortium (IPAC)
Posted : 12/06/2006     ID ：EPA-HQ-OAR-2006-0159-0031     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Comment submitted by David Doniger, Center Policy Director, Natural Resources Defense Council
Posted : 12/06/2006     ID ：EPA-HQ-OAR-2006-0159-0032     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Comment submitted by Pamela Wexler, Esq., Advisor and Fran Du Melle, American Thoracic Society (ATS) on behalf of US Stakeholders Group on MDI Transition
Posted : 12/06/2006     ID ：EPA-HQ-OAR-2006-0159-0034     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Comment submitted by Carl Dabruzzi, Business Developer Manager, 3M Pharmaceuticals/3M Drug Delivery Systems (3M)
Posted : 12/06/2006     ID ：EPA-HQ-OAR-2006-0159-0035     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Comment submitted by Kristen D.W. Morris, Vice President, Government Affairs & Public Policy, Boehringer Ingelheim Pharmaceuticals, Inc.
Posted : 12/06/2006     ID ：EPA-HQ-OAR-2006-0159-0036     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Comment submitted by James Losey Skadden Arps Slate Meagher & Flom LLP on behalf of GlaxoSmithKline (GSK)
Posted : 12/06/2006     ID ：EPA-HQ-OAR-2006-0159-0037     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Placeholder for CBI Comments submitted by Robert M. Sussman of Latham and Watkins LLP, Council for Amphastar Pharmaceuticals, Inc. and Armstrong Pharmaceuticals, Inc.
Posted : 01/03/2007     ID ：EPA-HQ-OAR-2006-0159-0038     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Public Comment Received from Rebecca Kuligowski
Posted : 01/03/2007     ID ：EPA-HQ-OAR-2006-0159-0039     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Placeholder for LATE CONFIDENTIAL comment received by EPA from Schering-Plough on February 5, 2007
Posted : 02/22/2007     ID ：EPA-HQ-OAR-2006-0159-0040     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Placeholder for LATE CONFIDENTIAL comment received by EPA from Robert M. Sussman of Latham and Watkins, LLC, counsel for Amphastar Pharmaceuticals Inc., and Armstrong Pharmaceuticals, Inc. on February 5, 2007
Posted : 02/22/2007     ID ：EPA-HQ-OAR-2006-0159-0041     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Placeholder for CBI comment received by EPA
Posted : 02/22/2007     ID ：EPA-HQ-OAR-2006-0159-0042     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Feb 5- Redacted Version of Schering-Plough Comments
Posted : 06/07/2007     ID ：EPA-HQ-OAR-2006-0159-0045     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

March 1- Redacted Version of Schering-Plough Comments
Posted : 06/07/2007     ID ：EPA-HQ-OAR-2006-0159-0046     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Redacted Version of Comments Submitted by Armstrong Pharmaceuticals, Inc.
Posted : 06/07/2007     ID ：EPA-HQ-OAR-2006-0159-0047     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET

Redacted Version of Comments Submitted by 3M Pharmaceuticals
Posted : 06/07/2007     ID ：EPA-HQ-OAR-2006-0159-0048     Agency : EPA

Comment Period Closed
Dec 04,2006 11:59 PM ET